Search research articles
Contact Us
Filters
Showing results (141-150 of 231) with videos related to
Page
of 24
Sort By:
Molecular Oncology
|
November 14, 2013
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing
Leticia De Mattos-Arruda, Francois-Clement Bidard, Helen H Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2018
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S Rugo, Javier Cortes, Ahmad Awada, et al.
The Lancet. Oncology
|
October 3, 2014
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
Gunter von Minckwitz, Fabio Puglisi, Javier Cortes, et al.
Clinical Breast Cancer
|
November 5, 2020
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Erika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Hope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Breast (Edinburgh, Scotland)
|
March 10, 2023
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
Laura Pala, Tommaso De Pas, Eleonora Pagan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 7, 2020
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer
Min Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2023
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Fabio Conforti, Laura Pala, Tommaso De Pas, et al.
Nature Reviews. Clinical Oncology
|
April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours
Maximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
Page
of 24
Search research articles
Search
Showing results (141-150 of 231) with videos related to
Sort By:
Page
of 24
Molecular Oncology
|
November 14, 2013
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing
Leticia De Mattos-Arruda, Francois-Clement Bidard, Helen H Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2018
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S Rugo, Javier Cortes, Ahmad Awada, et al.
The Lancet. Oncology
|
October 3, 2014
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
Gunter von Minckwitz, Fabio Puglisi, Javier Cortes, et al.
Clinical Breast Cancer
|
November 5, 2020
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Erika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Hope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Breast (Edinburgh, Scotland)
|
March 10, 2023
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials
Laura Pala, Tommaso De Pas, Eleonora Pagan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 7, 2020
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer
Min Huang, Joyce O'Shaughnessy, Jing Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2023
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Fabio Conforti, Laura Pala, Tommaso De Pas, et al.
Nature Reviews. Clinical Oncology
|
April 21, 2023
Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours
Maximilian J Mair, Rupert Bartsch, Emilie Le Rhun, et al.
Page
of 24